Clinical trials: Rectal Cancers
Metastatic Colorectal Cancer (CRC)
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06825624
- Testing
- HS-20093, Bevacizumab, 5-FU
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Hansoh BioMedical R&D Company
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT05605522
- Testing
- [225]-FPI-2059, [111In]-FPI-2058
- Where
- 8 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- 3B Pharmaceuticals GmbH
Adenoma, Colo-rectal Cancer
A Dual Tandem Study - SC vs. CAD-EYE vs. CAD-EYE With G-EYE
Single-center, four-arm dual-tandem, randomized, open-label study involving the following devices: 1. The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques …
- Trial name
- NCT05318495
- Testing
- Standard Colonoscopy, CAD-EYE, G-EYE
- Where
- Germany
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Dr. Horst Schmidt Klinik GmbH
Colon Cancer, Rectal Cancer
Clinical Trial in Patients With Metastatic Colorectal Cancer
The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and…
- Trial name
- NCT00081627
- Testing
- CoFactor and 5FU
- Where
- 9 sites in United States, Serbia and Montenegro
- Volunteers
- 48 people
- Sponsor
- Mast Therapeutics, Inc.
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
This two-stage study is designed to compare the safety and activity between RRx-001 against regorafenib followed by irinotecan-based therapies in a parallel comparative study.
- Trial name
- ROCKET (NCT02096354)
- Testing
- RRx-001, Regorafenib, Irinotecan
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- EpicentRx, Inc.
High Risk (Above Average) Subjects, Non Compliant Patients for Colo Rectal Cancer [CRC] Screening
Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects
The purpose of this study is to establish the efficacy of Check-Cap's C-Scan System in providing structural information on colonic polypoid lesions and masses, as an adjacent tool to Feacal Immunochemical Test [FIT] in high risk…
- Conditions
- High Risk (Above Average) Subjects, Non Compliant Patients for Colo Rectal Cancer [CRC] Screening, Counterindicated Patients for Colonoscopy
- Trial name
- NCT03356002
- Testing
- C-Scan System
- Where
- 7 sites in Israel
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Check-Cap Ltd.
Squamous Cell Carcinoma of the Anal Canal
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including…
- Trial name
- NCT06910137
- Testing
- retifanlimab
- Sponsor
- Incyte Corporation
Metastatic Colorectal Cancer
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
This is a multicenter, open-label study enrolling a total of up to 23 patients.
- Trial name
- NCT00873756
- Testing
- FOLFOX regimen, bevacizumab, dulanermin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Genentech, Inc.
Cancer, Carcinoma
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.
- Conditions
- Cancer, Carcinoma, Colon Cancer, Colorectal Cancer
- Trial name
- NCT00752570
- Testing
- AMG 386, FOLFIRI
- Volunteers
- 144 people
- Sponsor
- Amgen
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Colorectal Cancer, Gastrointestinal Cancer
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
The FOLFOX6 regimen is a standard chemotherapy regimen for the treatment of patients with colorectal cancer and other gastrointestinal cancers.
- Trial name
- NCT00660153
- Testing
- Tivozanib (AV-951) plus FOLFOX6
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumors
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib
- Trial name
- NCT00739453
- Testing
- OSI-906, erlotinib
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer, Prostate Cancer
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
This is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of [177Lu]Lu-A9-0631 and [225Ac]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, GRPR-positive Solid Tumors
- Trial name
- NCT07661641
- Testing
- [68Ga]Ga-A9-6217, Low dose [177Lu]Lu-A9-0631, [177Lu]Lu-A9-0631
- Where
- 2 sites in Australia
- Volunteers
- 115 people
- Sponsor
- Alpha-9 Oncology USA Inc.
Colorectal Cancer
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
This study will determine if nimotuzumab provides a benefit in this type of cancer when given in combination with irinotecan. The study will test: How long any good effects last. How bad any side effects are.
- Trial name
- NCT00493857
- Testing
- Nimotuzumab Humanized Monoclonal Antibody, Nimotuzumab
- Where
- 12 sites in Canada
- Volunteers
- 100 people
- Sponsor
- YM BioSciences
Metastatic Colorectal Cancer (mCRC)
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer…
- Trial name
- NCT06089330
- Testing
- JMT101, SG001, Irinotecan
- Volunteers
- 102 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Urine Metabolites in the Diagnosis of Disease
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.
- Conditions
- Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
- Trial name
- NCT06710067
- Where
- 4 sites in United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Luventix, Inc.
Solid Neoplasms, Colorectal Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
- Conditions
- Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
- Trial name
- NCT03833700
- Testing
- E7386
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.